SYDNEY, Australia--(BUSINESS WIRE)--Proteome Systems Limited (ASX Code:PXL) announced today that it has ceased development of a diagnostic test for Prostate Cancer. This decision is based on the results of a Proof of Concept study that demonstrated the project did not satisfy internal assessment hurdles.
